The Motley Fool on MSN1d
Is Viking Therepautics a Buy Now?Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.
Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...
As Viking Therapeutics continues to advance its clinical programs, the implications for patients and investors are substantial. The promising early results from VK2735 not only signify a potential ...
US stocks slumped on Monday as investors eagerly wait for the outcome of the US Presidential election on Tuesday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback